MBX Biosciences MBX 深 滬
等待開盤 09-23 09:30:00 美东时间
61.98
+1.040
+1.71%
華盛通- 最 高63.45
- 今 開61.14
- 成交量 43.34万股
- 最 低 60.84
- 昨 收 60.94
- 總市值 29.85亿
- 52周最高 72.64
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 12.94
- 委 比 26.58%
- 總股本 4816.01万
- 歷史最高 72.64
- 量 比 0.47
- 振 幅 4.28%
- 歷史最低 4.8069
- 每 手 1
- 風險率 15.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
MBX Biosciences appoints Jeff Held as Chief Legal Officer. With over 30 years of experience in biotech and healthcare, Held will support the company's growth and strategic initiatives. MBX granted him an inducement equity award, including stock options and RSUs, as part of his appointment. The company focuses on developing precision peptide therapies for endocrine and metabolic disorders.
09-08 12:00
MBX Biosciences Begins Pivotal Phase 3 Canvuparatide Trial
MBX Biosciences, Inc. ( ($MBX) ) just unveiled an update. On August 27, 2026, M...
08-27 20:58
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
08-22 03:01
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
08-11 02:11
MBX Biosciences GAAP EPS of -$0.78
MBX Biosciences press release (MBX): Q2 GAAP EPS of -$0.78. Cash and Cash Equivalents and Marketable Securities: As of June 30, 2026, MBX had cash, cash equivalents and marketable securities of $418.6...
08-06 20:19
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported Q2 2026 financial results with $418.6 million in cash and investments, supporting operations into 2029. Key highlights include: Phase 2 and one-year OLE data for weekly canvuparatide showing sustained benefit for chronic hypoparathyroidism, with Phase 3 trial recruitment ongoing. Initial Phase 1 data for monthly dosing MBX 4291 in obesity showed 7% weight loss. MBX 6180, a triple GLP-1/GIP/GCG agonist, was nominated as a ...
08-06 12:00
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
07-29 23:50
